Biotron Limited (BIT.AX)
AUD 0.02
(-5.88%)
AUD 0.02
(-5.88%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -5.15 Million AUD | -2.23% |
| 2023 | -5.03 Million AUD | -81.31% |
| 2022 | -2.77 Million AUD | 35.62% |
| 2021 | -4.31 Million AUD | -6.63% |
| 2020 | -4.04 Million AUD | -45.96% |
| 2019 | -2.77 Million AUD | -72.26% |
| 2018 | -1.61 Million AUD | 63.37% |
| 2017 | -4.39 Million AUD | -1.7% |
| 2016 | -4.32 Million AUD | -56.01% |
| 2015 | -2.77 Million AUD | 12.2% |
| 2014 | -3.15 Million AUD | 36.3% |
| 2013 | -4.95 Million AUD | -60.16% |
| 2012 | -3.09 Million AUD | -27.76% |
| 2011 | -2.42 Million AUD | -26.42% |
| 2010 | -1.91 Million AUD | -4.09% |
| 2009 | -1.84 Million AUD | 22.97% |
| 2008 | -2.38 Million AUD | 29.54% |
| 2007 | -3.38 Million AUD | -47.46% |
| 2006 | -2.29 Million AUD | 12.84% |
| 2005 | -2.63 Million AUD | 24.91% |
| 2004 | -3.51 Million AUD | -32.36% |
| 2003 | -2.65 Million AUD | -32.09% |
| 2002 | -2 Million AUD | -31.05% |
| 2001 | -1.53 Million AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.96 Million AUD | 0.0% |
| 2024 FY | -5.15 Million AUD | -2.23% |
| 2024 Q4 | -2.13 Million AUD | 0.0% |
| 2023 FY | -5.03 Million AUD | -81.31% |
| 2023 Q2 | -2.16 Million AUD | 0.0% |
| 2023 Q4 | -2.78 Million AUD | 0.0% |
| 2022 Q2 | -1.89 Million AUD | 0.0% |
| 2022 FY | -2.77 Million AUD | 35.62% |
| 2022 Q4 | -841.2 Thousand AUD | 0.0% |
| 2021 Q4 | -2.2 Million AUD | 0.0% |
| 2021 Q2 | -2.42 Million AUD | 0.0% |
| 2021 FY | -4.31 Million AUD | -6.63% |
| 2020 Q4 | -2.33 Million AUD | 0.0% |
| 2020 Q2 | -2.07 Million AUD | 0.0% |
| 2020 FY | -4.04 Million AUD | -45.96% |
| 2019 Q4 | -1.42 Million AUD | 0.0% |
| 2019 FY | -2.77 Million AUD | -72.26% |
| 2019 Q2 | -279.5 Thousand AUD | 0.0% |
| 2018 Q2 | -169.31 Thousand AUD | 0.0% |
| 2018 Q4 | -1.44 Million AUD | 0.0% |
| 2018 FY | -1.61 Million AUD | 63.37% |
| 2017 Q2 | -2.02 Million AUD | 0.0% |
| 2017 FY | -4.39 Million AUD | -1.7% |
| 2017 Q4 | -1.09 Million AUD | 0.0% |
| 2016 Q2 | -2.81 Million AUD | 0.0% |
| 2016 Q4 | -264.98 Thousand AUD | 0.0% |
| 2016 FY | -4.32 Million AUD | -56.01% |
| 2015 Q4 | -568.8 Thousand AUD | 0.0% |
| 2015 FY | -2.77 Million AUD | 12.2% |
| 2015 Q2 | -2.2 Million AUD | 0.0% |
| 2014 Q4 | -500.35 Thousand AUD | 0.0% |
| 2014 Q2 | -2.65 Million AUD | 0.0% |
| 2014 FY | -3.15 Million AUD | 36.3% |
| 2013 Q3 | -1.23 Million AUD | 49.6% |
| 2013 FY | -4.95 Million AUD | -60.16% |
| 2013 Q2 | -2.45 Million AUD | -217.8% |
| 2013 Q1 | -773.36 Thousand AUD | 0.0% |
| 2013 Q4 | -1.6 Million AUD | -29.56% |
| 2012 Q1 | -605.3 Thousand AUD | 0.0% |
| 2012 Q2 | -773.36 Thousand AUD | -27.76% |
| 2012 Q4 | -773.36 Thousand AUD | 0.0% |
| 2012 FY | -3.09 Million AUD | -27.76% |
| 2012 Q3 | -773.36 Thousand AUD | 0.0% |
| 2011 FY | -2.42 Million AUD | -26.42% |
| 2011 Q4 | -605.3 Thousand AUD | 0.0% |
| 2011 Q1 | -478.81 Thousand AUD | 0.0% |
| 2011 Q2 | -605.3 Thousand AUD | -26.42% |
| 2011 Q3 | -605.3 Thousand AUD | 0.0% |
| 2010 Q1 | -460.01 Thousand AUD | 0.0% |
| 2010 FY | -1.91 Million AUD | -4.09% |
| 2010 Q4 | -478.81 Thousand AUD | 0.0% |
| 2010 Q3 | -478.81 Thousand AUD | 0.0% |
| 2010 Q2 | -478.81 Thousand AUD | -4.09% |
| 2009 Q4 | -460.01 Thousand AUD | 0.0% |
| 2009 Q1 | -597.15 Thousand AUD | 0.0% |
| 2009 Q2 | -460.01 Thousand AUD | 22.97% |
| 2009 Q3 | -460.01 Thousand AUD | 0.0% |
| 2009 FY | -1.84 Million AUD | 22.97% |
| 2008 FY | -2.38 Million AUD | 29.54% |
| 2008 Q4 | -597.15 Thousand AUD | 0.0% |
| 2008 Q1 | -847.49 Thousand AUD | 0.0% |
| 2008 Q2 | -597.15 Thousand AUD | 29.54% |
| 2008 Q3 | -597.15 Thousand AUD | 0.0% |
| 2007 Q1 | -574.71 Thousand AUD | 0.0% |
| 2007 Q4 | -847.49 Thousand AUD | 0.0% |
| 2007 FY | -3.38 Million AUD | -47.46% |
| 2007 Q2 | -847.49 Thousand AUD | -47.46% |
| 2007 Q3 | -847.49 Thousand AUD | 0.0% |
| 2006 Q1 | -659.4 Thousand AUD | 0.0% |
| 2006 Q4 | -574.71 Thousand AUD | 0.0% |
| 2006 Q3 | -574.71 Thousand AUD | 0.0% |
| 2006 Q2 | -574.71 Thousand AUD | 12.84% |
| 2006 FY | -2.29 Million AUD | 12.84% |
| 2005 Q2 | -659.4 Thousand AUD | 24.91% |
| 2005 FY | -2.63 Million AUD | 24.91% |
| 2005 Q3 | -659.4 Thousand AUD | 0.0% |
| 2005 Q1 | -878.13 Thousand AUD | 0.0% |
| 2005 Q4 | -659.4 Thousand AUD | 0.0% |
| 2004 Q2 | -878.13 Thousand AUD | -32.36% |
| 2004 Q4 | -878.13 Thousand AUD | 0.0% |
| 2004 Q1 | -663.44 Thousand AUD | 0.0% |
| 2004 FY | -3.51 Million AUD | -32.36% |
| 2004 Q3 | -878.13 Thousand AUD | 0.0% |
| 2003 Q2 | -663.44 Thousand AUD | -32.09% |
| 2003 FY | -2.65 Million AUD | -32.09% |
| 2003 Q3 | -663.44 Thousand AUD | 0.0% |
| 2003 Q1 | -502.27 Thousand AUD | 0.0% |
| 2003 Q4 | -663.44 Thousand AUD | 0.0% |
| 2002 FY | -2 Million AUD | -31.05% |
| 2002 Q1 | -383.27 Thousand AUD | 0.0% |
| 2002 Q3 | -502.27 Thousand AUD | 0.0% |
| 2002 Q2 | -502.27 Thousand AUD | -31.05% |
| 2002 Q4 | -502.27 Thousand AUD | 0.0% |
| 2001 Q2 | -383.27 Thousand AUD | 0.0% |
| 2001 Q1 | - AUD | 0.0% |
| 2001 FY | -1.53 Million AUD | 0.0% |
| 2001 Q4 | -383.27 Thousand AUD | 0.0% |
| 2001 Q3 | -383.27 Thousand AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 2000 Q3 | - AUD | 0.0% |
| 2000 Q2 | - AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 153.014% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -253.031% |
| Zelira Therapeutics Limited | -5.93 Million AUD | 13.254% |
| Biome Australia Limited | -1.91 Million AUD | -169.238% |
| Patrys Limited | -3.53 Million AUD | -45.548% |
| Orthocell Limited | -11.68 Million AUD | 55.902% |
| Imugene Limited | -140.93 Million AUD | 96.345% |
| Noxopharm Limited | -7.53 Million AUD | 31.637% |
| PYC Therapeutics Limited | -38.85 Million AUD | 86.743% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | 58.153% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 28.321% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | 28.768% |
| Cynata Therapeutics Limited | -8.8 Million AUD | 41.517% |
| CSL Limited | 5.64 Billion AUD | 100.091% |
| Arovella Therapeutics Limited | -7.19 Million AUD | 28.387% |
| Bio-Gene Technology Limited | -3.06 Million AUD | -68.204% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 110.481% |
| Starpharma Holdings Limited | -15.15 Million AUD | 66.019% |
| Nanollose Limited | -1.24 Million AUD | -312.151% |
| Memphasys Limited | -2.7 Million AUD | -90.502% |
| Invex Therapeutics Ltd | -2.13 Million AUD | -141.428% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -150.475% |
| Amplia Therapeutics Limited | -4.42 Million AUD | -16.411% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | 64.958% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | -79.247% |
| Race Oncology Limited | -13.38 Million AUD | 61.503% |
| Nyrada Inc. | -4.56 Million AUD | -12.956% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Dimerix Limited | -25.05 Million AUD | 79.444% |
| PharmAust Limited | -6.65 Million AUD | 22.639% |
| Immutep Limited | -44.93 Million AUD | 88.537% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 88.502% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 73.721% |
| BTC Health Limited | 1.05 Million AUD | 588.13% |
| Acrux Limited | -9.83 Million AUD | 47.619% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 102.28% |
| Tissue Repair Ltd | -4.87 Million AUD | -5.644% |
| AdAlta Limited | -5.26 Million AUD | 2.099% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 89.089% |
| Hexima Limited | -1 Million AUD | -410.649% |
| AnteoTech Limited | -11.72 Million AUD | 56.073% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 92.089% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 76.64% |
| Avecho Biotechnology Limited | -4.58 Million AUD | -12.246% |
| Actinogen Medical Limited | -12.83 Million AUD | 59.879% |
| Immuron Limited | -5.8 Million AUD | 11.204% |
| Argenica Therapeutics Limited | -5.67 Million AUD | 9.17% |